Compare DexCom, Inc. (DXCM) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Synchrony Financial — how do they compare? DexCom, Inc. trades at $77.75 (market cap $28.06B), while Synchrony Financial trades at $74.18 (market cap $24.90B). The key difference: DexCom, Inc. and Synchrony Financial are close in size by market cap, and Synchrony Financial pays a 1.62% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SYF | |
|---|---|---|
Market Cap | $28.06B | $24.90B |
Sector | Health | Financials |
52-Week High | $89.53 | $88.47 |
52-Week Low | $54.84 | $63.78 |
Enterprise Value | $27.03B | — |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Synchrony Financial (SYF) trades at $74.11, up 0.58% with strong fundamentals including a 7.66 P/E ratio and 24.06% net income margin. The stock shows bearish technical signals despite three consecutive earnings beats, with Q2 2026 results expected on July 21. Recent corporate developments include executive leadership changes and new digital partnerships, while analyst consensus remains strongly bullish with a $86.38 price target.
SYF presents value opportunity with attractive valuation metrics and consistent earnings performance, though technical indicators suggest near-term pressure. Key risks include credit quality sensitivity to economic conditions and competitive pressures in consumer lending. The 16% upside to consensus target and zero sell ratings support the bullish analyst sentiment despite current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
